ArticleScientific reports2025
Mirabegron exhibits antibacterial and Immunomodulatory activities demonstrated by in vitro and in vivo studies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirabegron is a beta 3-adrenoceptor agonist that can help with incontinence, dysuria, and bladder overactivity. It alleviates the symptoms of prostate enlargement and urinary tract infections (UTIs) in the elderly. We aimed to explore Mirabegron's antimicrobial and immune-boosting properties, trying to benefit people suffering from urinary tract infections and having an overactive bladder. Mirabegron's putative antibacterial activity was investigated using the well diffusion method (In Vitro). Infected rats were treated with mirabegron (10 mg/kg, oral) and used for evaluation of immunomodulatory actions (In Vivo). We tested the antibacterial activity in vitro against numerous bacterial strains, including Escherichia coli (E. coli). The phagocytic activity and survival of peritoneal macrophages were examined. Also, serum levels of immunoglobulin G (IgG), immunoglobulin M (IgM), and interferon-γ (INF-γ) were estimated in E. coli-infected rats. We found that mirabegron exhibited significant antibacterial activity, particularly against E. coli. Phagocytic activity increased notably in vivo, indicating an improved innate immune response. Mirabegron also demonstrated a substantial rise in immunoglobulin and cytokine levels, enhancing acquired immunity. According to our findings, in vitro and in vivo tests of mirabegron revealed possible antibacterial activity as well as immunomodulatory properties. Mirabegron could alleviate symptomatic UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.